Advanced

Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines.

Carlsson, Fredrika LU ; Adler, SP; Lamarre, A and Ohlin, Mats LU (2007) In Vaccine 26(1). p.41-46
Abstract
Glycoprotein B (gB) is a major component in several vaccines that are under development for prevention of disease by cytomegalovirus. It contains multiple determinants that are targets for neutralizing antibodies. One of them is site I of antigenic domain 2 (AD-2). The epitope, defined by short peptides, is quite conserved between different isolates. However, it is poorly immunogenic in natural infection. In this study we investigated the extent to which different vaccines, attenuated live Towne vaccine with or without priming with a canarypox virus coding for gB, or a recombinant gB vaccine adjuvanted with MF59, induced antibodies to this epitope. As in natural infection only a fraction of all subjects developed antibody responses against... (More)
Glycoprotein B (gB) is a major component in several vaccines that are under development for prevention of disease by cytomegalovirus. It contains multiple determinants that are targets for neutralizing antibodies. One of them is site I of antigenic domain 2 (AD-2). The epitope, defined by short peptides, is quite conserved between different isolates. However, it is poorly immunogenic in natural infection. In this study we investigated the extent to which different vaccines, attenuated live Towne vaccine with or without priming with a canarypox virus coding for gB, or a recombinant gB vaccine adjuvanted with MF59, induced antibodies to this epitope. As in natural infection only a fraction of all subjects developed antibody responses against site I of AD-2 following vaccination. We suggest that strategies that enhance immunogenicity of this epitope will improve vaccine efficacy. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Viral/blood, Cytomegalovirus Vaccines/immunology, Epitope Mapping, Humans, Immunization, Protein Structure, Antibodies, Tertiary, Vaccines, Attenuated/immunology, Synthetic/immunology, Viral Envelope Proteins/chemistry, Viral Envelope Proteins/immunology
in
Vaccine
volume
26
issue
1
pages
41 - 46
publisher
Elsevier
external identifiers
  • pmid:18063447
  • wos:000252490700005
  • scopus:36749092916
ISSN
1873-2518
DOI
10.1016/j.vaccine.2007.10.048
language
English
LU publication?
yes
id
4c8d89e6-74bb-4906-be28-9b2b915f45af (old id 594348)
date added to LUP
2007-11-27 15:19:35
date last changed
2017-01-01 05:00:59
@article{4c8d89e6-74bb-4906-be28-9b2b915f45af,
  abstract     = {Glycoprotein B (gB) is a major component in several vaccines that are under development for prevention of disease by cytomegalovirus. It contains multiple determinants that are targets for neutralizing antibodies. One of them is site I of antigenic domain 2 (AD-2). The epitope, defined by short peptides, is quite conserved between different isolates. However, it is poorly immunogenic in natural infection. In this study we investigated the extent to which different vaccines, attenuated live Towne vaccine with or without priming with a canarypox virus coding for gB, or a recombinant gB vaccine adjuvanted with MF59, induced antibodies to this epitope. As in natural infection only a fraction of all subjects developed antibody responses against site I of AD-2 following vaccination. We suggest that strategies that enhance immunogenicity of this epitope will improve vaccine efficacy.},
  author       = {Carlsson, Fredrika and Adler, SP and Lamarre, A and Ohlin, Mats},
  issn         = {1873-2518},
  keyword      = {Viral/blood,Cytomegalovirus Vaccines/immunology,Epitope Mapping,Humans,Immunization,Protein Structure,Antibodies,Tertiary,Vaccines,Attenuated/immunology,Synthetic/immunology,Viral Envelope Proteins/chemistry,Viral Envelope Proteins/immunology},
  language     = {eng},
  number       = {1},
  pages        = {41--46},
  publisher    = {Elsevier},
  series       = {Vaccine},
  title        = {Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines.},
  url          = {http://dx.doi.org/10.1016/j.vaccine.2007.10.048},
  volume       = {26},
  year         = {2007},
}